Before signing up to participate in a clinical trial and giving informed consent, a patient must consider a range of factors, including potential adverse events, and the more information that patient has — and the easier that information is to digest — the odds of a better patient experience and more successful trial increase.
FDA Advisory Committee Focuses On Improving Informed Consent For Patients Volunteering For Device Trials
The US FDA’s Patient Engagement Advisory Committee met Wednesday to discuss ways the agency can empower patients thinking about whether to participate in clinical trials of regulated medical products. Central to the committee’s discussion was not only the type of information patients need to evaluate when considering joining a study, but how that information should be presented to them.
More from Medtech Insight
More from Policy & Regulation
The Doctor Patient Forum says the US FDA should regulate a scoring platform from Bamboo Health intended to help clinicians calculate risk for opioid abuse as a medical device to ensure patient safety.
• By
A new set of clinical lab regulations, which came into effect in January, include higher fees, an expanded set of possible consequences for labs that are not in compliance, and revised employee standards.
• By
With the support of AIM-MASH AI Assist only one pathologist is needed to reliably make a histology assessment of inflammatory liver disease to decide whether patients should be included in MASH clinical trials.